AA Amyloidosis
Conditions
Keywords
amyloidosis, renal transplantation
Brief summary
End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.
Detailed description
AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.
Interventions
None listed
Sponsors
Istanbul University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Renal transplantation recipients whose primary renal disease is AA amyloidosis; patients with allograft biopsy-confirmed AA amyloidosis (for study group) and patients with no clinical or laboratory signs of recurrence in the renal allograft (for control group 1) * Renal transplantation recipients whose primary diseases are other than AA amyloidosis (for control group 2)
Exclusion criteria
* Patients who are unwilling or unable to consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Allograft survival | 1 - 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Allograft rejection | 1 - 5 years |
Countries
Turkey (Türkiye)
Outcome results
None listed